1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Respiratory Syncytial Virus: Epidemiology Forecast in Asia-Pacific Markets to 2028

Respiratory Syncytial Virus: Epidemiology Forecast in Asia-Pacific Markets to 2028

  • October 2019
  • 43 pages
  • ID: 5825159
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Respiratory Syncytial Virus: Epidemiology Forecast in Asia-Pacific Markets to 2028

Summary
Respiratory syncytial virus (RSV) is a common respiratory infection that most children will be infected with by the time they are two years old.In healthy individuals RSV usually self-resolves within a week or two without need for significant therapeutic intervention.

In preterm and very young infants, the elderly, or those with otherwise compromised immune systems, however, RSV can cause severe illness or death.

It has been estimated that up to 30 million episodes of RSV-related lower respiratory infection occur annually worldwide, with the majority of those cases occurring in low-income countries.RSV is also considered to be the leading cause of bronchiolitis and pneumonia in children less than one year old and one of the leading causes of respiratory disease in older adults.

Currently RSV has neither a known cure nor a vaccine; however, preventive measures can be taken to help mitigate the spread of the disease

Epidemiologists provide a well-rounded, evidence-based analysis and forecast for the hospitalized and prophylactic populations for RSV in this report.This analysis covered all at-risk groups that are recommended for RSV prophylactic treatment.

Each population, including the hospitalized population, is also segmented by ages and by sex, thereby providing a granular visualization of the RSV prophylactic and hospitalized markets in the 5GM.

Scope
- The Respiratory Syncytial Virus (RSV) Epidemiology Report and Model provide an overview of the risk factors and global trends RSV in the five growth markets (5GM: Japan, Australia, urban China, India, and South Korea).
- This report also includes a 10-year epidemiology forecast for the pediatric and adult populations hospitalized due to RSV infection (hospitalized population) in the 5GM, in addition to the pediatric and adult populations that are most at risk for severe RSV infection and are therefore eligible to receive prophylactic treatment (prophylactic population). The prophylactic population consists of: children born before 37 weeks of gestation (preterm population); preterm births with neonatal chronic lung disease (CLD); live births with hemodynamically significant congenital heart disease; boys, 0-2 years old, with Duchenne muscular dystrophy (DMD); children, 0-2 years old, with spinal muscular atrophy (SMA); pregnant women in the third trimester; adults ages 55 years or older living in nursing homes (long-term-care institutions).
- The RSV epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 5GM.
- The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy
The RSV Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global RSV market.
- Quantify patient populations in the global RSV market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for RSV therapeutics in each of the markets covered.
- Understand magnitude of RSV population by both therapeutic and prophylactic markets.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Multiple Sclerosis: Epidemiology Forecast to 2028

Multiple Sclerosis: Epidemiology Forecast to 2028

  • $ 3995
  • November 2019

Multiple Sclerosis: Epidemiology Forecast to 2028SummaryMultiple sclerosis (MS) is an autoimmune disease affecting principally the central nervous system that causes nerve sheath demyelination followed ...

Psoriatic Arthritis: Epidemiology Forecast to 2028

Psoriatic Arthritis: Epidemiology Forecast to 2028

  • $ 3995
  • November 2019

Psoriatic Arthritis: Epidemiology Forecast to 2028SummaryImprovements in identifying and diagnosing Psoriatic Arthritis (PsA), a chronic inflammatory arthropathy, are increasing the number of diagnosed ...

Mechanical Circulatory Support Devices - Medical Devices Pipeline Assessment, 2019

Mechanical Circulatory Support Devices - Medical Devices Pipeline Assessment, 2019

  • $ 4000
  • December 2019

Mechanical Circulatory Support Devices - Medical Devices Pipeline Assessment, 2019SummaryMedical Devices sector report, “Mechanical Circulatory Support Devices - Medical Devices Pipeline Assessment, ...


ref:plp2019

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on